1. Home
  2. NTRA vs BAM Comparison

NTRA vs BAM Comparison

Compare NTRA & BAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • BAM
  • Stock Information
  • Founded
  • NTRA 2003
  • BAM 2022
  • Country
  • NTRA United States
  • BAM Canada
  • Employees
  • NTRA N/A
  • BAM N/A
  • Industry
  • NTRA Medical Specialities
  • BAM
  • Sector
  • NTRA Health Care
  • BAM
  • Exchange
  • NTRA Nasdaq
  • BAM Nasdaq
  • Market Cap
  • NTRA 22.1B
  • BAM 21.8B
  • IPO Year
  • NTRA 2015
  • BAM N/A
  • Fundamental
  • Price
  • NTRA $162.31
  • BAM $58.57
  • Analyst Decision
  • NTRA Strong Buy
  • BAM Buy
  • Analyst Count
  • NTRA 17
  • BAM 11
  • Target Price
  • NTRA $165.88
  • BAM $53.68
  • AVG Volume (30 Days)
  • NTRA 1.3M
  • BAM 1.8M
  • Earning Date
  • NTRA 02-27-2025
  • BAM 02-12-2025
  • Dividend Yield
  • NTRA N/A
  • BAM 2.99%
  • EPS Growth
  • NTRA N/A
  • BAM 13.27
  • EPS
  • NTRA N/A
  • BAM 1.28
  • Revenue
  • NTRA $1,531,955,000.00
  • BAM N/A
  • Revenue This Year
  • NTRA $56.11
  • BAM N/A
  • Revenue Next Year
  • NTRA $9.76
  • BAM $14.66
  • P/E Ratio
  • NTRA N/A
  • BAM $174.95
  • Revenue Growth
  • NTRA 54.94
  • BAM N/A
  • 52 Week Low
  • NTRA $69.91
  • BAM $37.29
  • 52 Week High
  • NTRA $183.00
  • BAM $62.61
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 40.88
  • BAM 52.21
  • Support Level
  • NTRA $168.15
  • BAM $54.48
  • Resistance Level
  • NTRA $180.41
  • BAM $61.47
  • Average True Range (ATR)
  • NTRA 7.08
  • BAM 1.62
  • MACD
  • NTRA -1.24
  • BAM 0.09
  • Stochastic Oscillator
  • NTRA 14.58
  • BAM 58.50

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About BAM Brookfield Asset Management Inc Limited Voting Shares

Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.

Share on Social Networks: